Every material Form 8-K Chemed filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chemed reported third-quarter 2025 results for the period ended September 30, 2025, with revenue up 3.1% to $624.9 million while GAAP diluted EPS fell 10.8% to $4.46 and adjusted diluted EPS fell 6.6% to $5.27. The company reiterated its 2025 adjusted diluted EPS guidance of $22.00 to $22.30 per share.
Revenue rose 3.1% to $624.9 million; VITAS net revenue rose 4.2% to $407.7 million and Roto-Rooter revenue rose 1.1% to $217.2 million.
GAAP diluted EPS was $4.46, down from $5.00 a year earlier; adjusted diluted EPS was $5.27, down 6.6%.
Consolidated Adjusted EBITDA was $109.0 million, compared with $123.0 million in the prior-year quarter, per the EBITDA reconciliation.
2025 guidance of $22.00 to $22.30 per share was reiterated and assumes no Medicare Cap for the Florida combined program from October 1, 2025.
Chemed reported second-quarter 2025 revenue up 3.8% to $618.8 million, but GAAP diluted earnings per share fell 23.2% to $3.57. The company cut its full-year 2025 EPS guidance to $22.00 to $22.30 from $24.95 to $25.45, citing a larger Medicare Cap billing limitation at VITAS, and said VITAS CEO Nicholas M. Westfall is resigning, with Joel L. Wherley to succeed him.
Q2 2025 revenue rose 3.8% to $618.8 million; GAAP diluted EPS was $3.57, down 23.2%, and adjusted diluted EPS was $4.27, down 21.9%.
Full-year 2025 EPS guidance revised to $22.00 to $22.30, versus the previously issued $24.95 to $25.45.
VITAS estimates a $19 million Florida Medicare Cap billing limitation for the cap year ending September 30, 2025, and accrued $16.4 million in Q2 2025.
Nicholas M. Westfall resigns as Chairman and CEO of VITAS effective July 29, 2025, and will remain an Executive Vice President through December 1, 2025; Joel L. Wherley will succeed him as VITAS CEO.
Chemed Corporation reported first-quarter 2025 results for the period ended March 31, 2025, with revenue up 9.8% to $646.9 million and GAAP diluted EPS up 14.6% to $4.86. VITAS revenue and profit grew, while Roto-Rooter adjusted EBITDA fell 2.4%, and the company said it will provide updated 2025 earnings guidance with its June 30, 2025 release.
Revenue increased 9.8% to $646.9 million; GAAP diluted EPS was $4.86, up 14.6%.
Adjusted diluted EPS was $5.63, up 8.3%.
VITAS net patient revenue rose 15.1% to $407.4 million; Roto-Rooter revenue rose 1.8% to $239.5 million.
Roto-Rooter adjusted EBITDA fell 2.4% to $59.2 million; the company will update 2025 guidance on June 30, 2025.
Chemed reported fourth-quarter 2024 revenue of $640.0 million, up 9.2%, with GAAP diluted EPS of $6.02, up 2.0%, and adjusted diluted EPS of $6.83, up 3.5%. The company guided to full-year 2025 adjusted diluted EPS of $24.95 to $25.45, compared with $23.13 in 2024, while Roto-Rooter revenue and adjusted EBITDA declined in the quarter.
Q4 2024 revenue $640.0 million, up 9.2%; VITAS net patient revenue up 17.4% to $411.0 million
Roto-Rooter Q4 revenue fell 2.9% to $229.0 million and adjusted EBITDA fell 7.2% to $60.3 million
2025 guidance: adjusted diluted EPS of $24.95 to $25.45 versus $23.13 for 2024; Roto-Rooter revenue growth of 2.4% to 3.0%
Repurchased 388,235 shares for $212.8 million in the quarter; about $255.3 million of authorization remained at December 31, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Chemed filing is on SEC EDGAR ↗. 8-K briefs of other companies →